How does treatment management change with a positive intramammary lymph node in the setting of a negative axilla, with the inclusion of these as N1 node in the AJCC 8th edition?

I don’t think anything would change for management as I would treat the same RT field and a med onc would follow the same principle of using genomic assay (or phenotype) to decide about systemic treatment.